- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02841436
A Clinical Research About Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer
July 2, 2020 updated by: National Taiwan University Hospital
Pancreatic cancers is one the most important malignancies with highest mortality in the world.
The prognosis of these patients is very poor.
Although some patients with early-diagnosed disease could receive surgical intervention, a majority (70%to 80%) of patients present with locally advanced or metastatic status are inoperable.
Patients in this late status usually are recommended to receive palliative bypass operation such as choledochojejunostomy and/or gastrojejunostomy and palliative radiotherapy for the pancreatic cancer.
Radiofrequency ablation (RFA) used to be expected an alternative therapy.
However, the main drawback of RFA is its side effect to damage adjacent structure such as bile duct, and the tumors located adjacent to vessels could not be ablated well.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Irreversible electroporation (IRE), developed and manufactured by AngioDynamics US Ltd, can ablate tumor by fenestrating the cancer cell membrane by electric pulse.
The anti-tumor effect does not result from thermotherapy, so is also not diminished by adjacent vessels.
Several pre-clinical and clinical studies have already demonstrated IRE is a safe and effective treatment, and the adjacent tissue such as vessels and ductal structures will be spared.
Recently, IRE had been used to treat pancreatic cancer successfully, and the safety is satisfactory.
The system has been approved as safe by the European Union (EU) in 2008 and received Food and Drug Administration (FDA) approval in 2010.
However, there are still few experiences in using IRE for tumor ablation in Taiwan.
In this study, the investigators will perform IRE for inoperable patients with locally advanced pancreatic cancers.
They will receive IRE during the operation of palliative bypass operation including choledochojejunostomy and/or gastrojejunostomy.
The investigators will evaluate the potential side effect and ablate effect of tumors, and also follow-up the patients for 2 years to evaluate the overall survival.
The investigators will appraisal the clinical feasibility and advantage of the system by this study.
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for this study:
- Locally advanced pancreatic cancer is defined as per the 7th edition of the American Joint Committee on Cancer (AJCC) staging system for pancreatic cancer -described as arterial encasement of either the celiac axis or superior mesenteric artery or both.
- Biliary tract or intestine is compromised by tumor, palliative bypass operation (hepaticojejunostomy and/or gastrojejunostomy) is considered to be performed.
- Eastern Cooperative Oncology Group (ECOG) score of 0-1,
- American Society of Anaesthesiologists (ASA) score ≤ 3,
- Adequate bone marrow, liver and renal function. Platelet count ≥ 100 K/Μl. Total bilirubin ≦ 5 mg/dL. alanine transaminase (ALT) and aspartate transaminase (AST) < 5 x upper limit of normal. prothrombin time (PT)- international normalized ratio (INR) ≦ 2.0 (5). Serum creatinine ≦ 1.5 x upper limit of normal
- Prior Informed Consent Form
- Life expectancy of at least 3 months.
Exclusion Criteria:
Patients presenting with any of the following will not be enrolled into this study:
- History of cardiac disease:
- Congestive heart failure >New York Heart Association (NYHA) class 2
- Active coronary artery disease (CAD) (myocardial infarction more than 6 months prior to study entry is allowed)
- Cardiac arrhythmias (>Grade 2 NCI-CTCAE Version 3.0) which are poorly controlled with anti-arrhythmic therapy or requiring pace maker
- Uncontrolled hypertension
- Any active metal implanted device (eg Pacemaker),
- Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
- Received treatment with an investigational agent/ procedure within 30 days prior to treatment with the IRE System,
- Known history of human immunodeficiency virus (HIV) infection
- Patients with resectable lesions.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: irreversible electroporation (IRE)
IRE (AngioDynamics, NY) To use 2 to 6 unipolar electrodes in a predetermined grid pattern.
90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response
Time Frame: 1 month after treatment
|
Tumor response will be evaluated by abdominal computed tomography (CT) or magnetic resonance imaging (MRI).
|
1 month after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eastern Cooperative Oncology Group (ECOG) evaluation
Time Frame: one to two years
|
Complete an Eastern Cooperative Oncology Group (ECOG) evaluation
|
one to two years
|
Haematology test
Time Frame: one to two years
|
complete white blood cell count with differential, red blood cell count, hemoglobin, hematocrit, and platelets
|
one to two years
|
Tumor marker measurement
Time Frame: one to two years
|
measure the change of tumor marker such as carcinoembryonic antigen (CEA)
|
one to two years
|
Conduct computed tomography (CT) or magnetic resonance imaging (MRI) scans for tumour response evaluation
Time Frame: one to two years
|
Subjects will still be followed-up in the event of disease progression in order to document overall survival, a secondary endpoint.
|
one to two years
|
Review concomitant medications
Time Frame: one to two years
|
Use of medications will be reviewed and recorded
|
one to two years
|
Assess for presence of adverse event
Time Frame: one to two years
|
An adverse event assessment will be performed
|
one to two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (ACTUAL)
June 16, 2014
Study Completion (ACTUAL)
May 27, 2020
Study Registration Dates
First Submitted
June 27, 2016
First Submitted That Met QC Criteria
July 19, 2016
First Posted (ESTIMATE)
July 22, 2016
Study Record Updates
Last Update Posted (ACTUAL)
July 7, 2020
Last Update Submitted That Met QC Criteria
July 2, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201210008DIC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
Clinical Trials on Irreversible Electroporation (IRE) System
-
Jewish General HospitalNot yet recruiting
-
University Hospital Inselspital, BerneTerminated
-
Fuda Cancer Hospital, GuangzhouCompletedHilus Pulmonary NeoplasmsChina
-
Fuda Cancer Hospital, GuangzhouCompletedUterine Cervical NeoplasmsChina
-
Fuda Cancer Hospital, GuangzhouCompletedLung Neoplasms Accompanied by Respiratory Function InsufficiencyChina
-
Fuda Cancer Hospital, GuangzhouWithdrawnProstatic NeoplasmsChina
-
Fuda Cancer Hospital, GuangzhouCompletedGallbladder NeoplasmsChina
-
Fuda Cancer Hospital, GuangzhouCompleted
-
Fuda Cancer Hospital, GuangzhouCompletedEsophageal NeoplasmsChina
-
Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryRecruitingUnresectable Pancreatic CancerDenmark